The company said its revenue grew 24 per cent to Rs 20,558 million during the quarter and posted adjusted Ebitda margin at 18.5 per cent. The board has recommended an interim dividend of Rs 19 per share, and the record date for this payout will be February 3, 2023.
The IT firm also said its total income was at Rs 37,468 lakh in the third quarter, which is a growth of 4.3 per cent over last year's figure. It also posted earnings before interest, taxes, depreciation, and amortisation (Ebitda) of Rs 9,726 lakh, which is a 26.5 per cent growth.
Mumbai (Maharashtra) [India], January 18 (ANI/PNN): SVP Global Textiles Ltd, one of the largest compact cotton yarn manufacturers and leading multinational textiles company, has reported a Total Income from Operations of Rs 301.81 crores for the quarter ended December 2022, rise of 2.62 per
BofA Securities also expects Paytm's momentum in the lending business as well as its merchant traction to remain strong in Q3. Analysts at ICICI Securities in January 4, 2023, estimated an 11 per cent quarter-on-quarter operating revenue growth on the back of increasing GMV and lending bu
The company's total income (or total revenue) for Q2 FY23 was Rs 22,409 million, an increase of 5.1 per cent over Q2 FY22. The company in a statement said its adjusted operating profit or earnings before interest, taxes, depreciation, and amortisation (Ebitda) for Q2 FY23 was Rs 18,209 milli
Mumbai (Maharashtra) [India], November 15 (ANI/PNN): SVP Global Textiles Ltd, one of the largest compact cotton yarn manufacturers and leading multinational textiles company has reported a Total Income from Operations of Rs 294.1 crore for the quarter ended September 2022, rise of 4.9 per ce
Bengaluru (Karnataka) [India], November 15 (ANI/NewsVoir): Biocon Ltd, an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the second quarter ended September 30, 2022.
The New Delhi-headquartered company said its operating profit and Earnings before interest, taxes, depreciation, and amortisation (Ebitda) grew 74.1 per cent to Rs 88.4 crore in the reviewed quarter, against Rs 50.8 crore in the year-ago period.
The pharmaceutical firm's net revenue went down 3.4 per cent to Rs 5,739 crore against Rs 5,941 crore in the corresponding period the previous year.
Net Ebitda of the company went down 33 per cent to Rs 790 crore against Rs 1,186 crore in the year-ago period.
The Hyderabad-headquartered firm said its revenues grew 52.48 per cent to Rs 1,683.07 crore on a year-on-year basis. The company also said operating profit or Ebitda also rose 45.07 per cent YoY.